Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-04Clinical Trial Update: Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy [Phase 2]
Phase 2 trial evaluating imatinib mesylate in newly diagnosed acute myeloid leukemia patients who have received chemotherapy has completed; …
-
CLINICAL_TRIALS trial_result · 2020-03-03Clinical Trial Update: IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT [Phase 2, Phase 3]
Phase 2/3 clinical trial comparing IDA+BUCY conditioning to BUCY conditioning for intermediate-risk acute myeloid leukemia patients undergoi…
-
CLINICAL_TRIALS trial_result · 2020-03-03Clinical Trial Update: Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older [Phase 1]
Phase 1 trial of MLN4924 (pevonedistat) in combination with azacitidine in treatment-naive patients aged 60 and older with acute myeloid leu…
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy [Phase 3]
A Phase 3 study comparing venetoclax plus low-dose cytarabine versus low-dose cytarabine alone in treatment-naive acute myeloid leukemia pat…
-
CLINICAL_TRIALS trial_result · 2020-02-27Clinical Trial Update: Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 [Phase 2]
Phase 2 trial investigating deferasirox, cholecalciferol, and azacitidine in newly diagnosed acute myeloid leukemia patients over 65; study …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) [Phase 1]
Phase 1 trial of ADCT-301 in relapsed/refractory CD25-positive AML or CD25-positive ALL was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating SU 11248 (Sutent) in combination with standard chemotherapy for FLT3-mutated acute myeloid leukemia in…
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
Phase 1/2 trial comparing CIA versus FLAI in acute myeloid leukemia and high-risk myelodysplastic syndrome completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: AC220 for Children With Relapsed/Refractory ALL or AML [Phase 1]
Phase 1 clinical trial update for AC220 in children with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia; study c…
-
CLINICAL_TRIALS trial_result · 2020-02-19Clinical Trial Update: T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) [Phase 2]
Phase 2 trial of Clofarabine, Etoposide, and Cyclophosphamide in relapsed acute myeloid leukemia was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: INCB018424 in Patients With Advanced Hematologic Malignancies [Phase 2]
Phase 2 trial of INCB018424 (ruxolitinib) in patients with advanced hematologic malignancies. Results for diseases including AML, ALL, MDS, …
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation [Phase 2]
Phase 2 trial of quizartinib in AML patients with FLT3-ITD mutation has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 [Phase 3]
A Phase 3 trial comparing haploidentical stem cell transplantation versus autologous stem cell transplantation (with or without decitabine) …
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine [Phase 1, Phase 2]
Phase 1/Phase 2 trial evaluating APR-246 in combination with azacitidine for myelodysplastic syndrome with gene mutation and acute myeloid l…
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive [Phase 3]
Open-label Phase 3 trial comparing quizartinib monotherapy to salvage chemotherapy in FLT3-ITD–positive AML has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Home or Away From Home - Descriptive Interviews (Aim 2)
Completed descriptive interviews study (Aim 2) related to pediatric acute myeloid leukemia; results posted 2020-01-27.
-
CLINICAL_TRIALS trial_result · 2020-01-23Clinical Trial Update: Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations [Phase 2, Phase 3]
A phase 2/3 trial evaluating the addition of one of two novel treatment agents to standard chemotherapy in acute myeloid leukemia and myelod…
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts [Phase 2]
A Phase 2 clinical trial evaluating T cell depletion in recipients of HLA haploidentical related donor stem cell grafts for various hematolo…
-
CLINICAL_TRIALS trial_result · 2020-01-14Clinical Trial Update: Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) [Phase 3]
Phase 3 clinical trial evaluating post-transplant azacitidine to prevent relapse in acute myeloid leukemia and myelodysplastic syndrome; tri…
-
CLINICAL_TRIALS trial_result · 2020-01-14Clinical Trial Update: Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission [Phase 2]
Phase 2 clinical trial evaluating chemo-sensitization before hematopoietic stem cell transplantation in patients with acute leukemia who are…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating idarubicin, cytarabine, and pravastatin for relapsed acute myeloid leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT [Phase 2]
Phase 2 clinical trial evaluating irradiation-based myeloablative conditioning followed by regulatory T cell and conventional T cell immunot…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease [Phase 1]
Phase 1 trial evaluating lenalidomide after allogeneic hematopoietic cell transplant in AML and MDS patients with minimal residual disease; …
-
CLINICAL_TRIALS trial_result · 2020-01-07Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating erlotinib hydrochloride in relapsed or refractory acute myeloid leukemia has completed with posted results…
-
CLINICAL_TRIALS trial_result · 2020-01-06Clinical Trial Update: Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation [Phase 2]
Phase 2 trial evaluating sorafenib in combination with 5-azacitidine as initial therapy for AML and high-risk MDS with FLT3-ITD mutation; tr…